Developing Scandium and Yttrium Coordination Chemistry to Advance Theranostic Radiopharmaceuticals

Overview

Journal Commun Chem

Publisher Springer Nature

Specialty Chemistry

Date 2023 Jan 27

PMID 36703424

Authors

Korey P Carter

Gauthier J-P Deblonde

Trevor D Lohrey

Tyler A Bailey

Dahlia D An

Katherine M Shield

Wayne W Lukens Jr

Rebecca J Abergel

Affiliations

Soon will be listed here.

Abstract

The octadentate siderophore analog 3,4,3-LI(1,2-HOPO), denoted 343-HOPO hereafter, is known to have high affinity for both trivalent and tetravalent lanthanide and actinide cations. Here we extend its coordination chemistry to the rare-earth cations Sc and Y and characterize fundamental metal-chelator binding interactions in solution via UV-Vis spectrophotometry, nuclear magnetic resonance spectroscopy, and spectrofluorimetric metal-competition titrations, as well as in the solid-state via single crystal X-ray diffraction. Sc and Y binding with 343-HOPO is found to be robust, with both high thermodynamic stability and fast room temperature radiolabeling, indicating that 343-HOPO is likely a promising chelator for in vivo applications with both metals. As a proof of concept, we prepared a Y-343-HOPO complex for in vivo PET imaging, and the results presented herein highlight the potential of 343-HOPO chelated trivalent metal cations for therapeutic and theranostic applications.

Citing Articles

Bioleaching of lanthanum from nickel metal hydride dry battery using siderophores produced by Pseudomonas sp.

Hegazy A, Soliman H, Mowafy A, Mohamedin A World J Microbiol Biotechnol. 2025; 41(2):39.

PMID: 39821467 PMC: 11739246. DOI: 10.1007/s11274-025-04250-9.

A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements.

Wood J, Ghosh S, Houston Z, Fletcher N, Humphries J, Mardon K Chem Sci. 2024; 15(30):11748-11760.

PMID: 39092114 PMC: 11290327. DOI: 10.1039/d4sc02851a.

Actinium chelation and crystallization in a macromolecular scaffold.

Wacker J, Woods J, Rupert P, Peterson A, Allaire M, Lukens W Nat Commun. 2024; 15(1):5741.

PMID: 39009580 PMC: 11251196. DOI: 10.1038/s41467-024-50017-5.

Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.

Kumari S, Raj S, Babu M, Bhatti G, Bhatti J Arch Pharm Res. 2023; 47(1):40-65.

PMID: 38153656 DOI: 10.1007/s12272-023-01479-6.

Metal-Ligand Interactions in Scandium Complexes with Radiopharmaceutical Applications.

Kovacs A Inorg Chem. 2023; 62(50):20733-20744.

PMID: 37949439 PMC: 10731654. DOI: 10.1021/acs.inorgchem.3c02211.

References

Sturzbecher-Hoehne M, Leung C, DAleo A, Kullgren B, Prigent A, Shuh D . 3,4,3-LI(1,2-HOPO): in vitro formation of highly stable lanthanide complexes translates into efficacious in vivo europium decorporation. Dalton Trans. 2011; 40(33):8340-6. DOI: 10.1039/c1dt10840a. View

Thiele N, Brown V, Kelly J, Amor-Coarasa A, Jermilova U, MacMillan S . An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy. Angew Chem Int Ed Engl. 2017; 56(46):14712-14717. DOI: 10.1002/anie.201709532. View

Hennrich U, Kopka K . Lutathera: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals (Basel). 2019; 12(3). PMC: 6789871. DOI: 10.3390/ph12030114. View

Hernandez R, Valdovinos H, Yang Y, Chakravarty R, Hong H, Barnhart T . (44)Sc: an attractive isotope for peptide-based PET imaging. Mol Pharm. 2014; 11(8):2954-61. PMC: 4128785. DOI: 10.1021/mp500343j. View

Moore E, Jocher C, Xu J, Werner E, Raymond K . An octadentate luminescent Eu(III) 1,2-HOPO chelate with potent aqueous stability. Inorg Chem. 2007; 46(14):5468-70. PMC: 3190975. DOI: 10.1021/ic700364t. View

Boros E, Packard A . Radioactive Transition Metals for Imaging and Therapy. Chem Rev. 2018; 119(2):870-901. DOI: 10.1021/acs.chemrev.8b00281. View

Umbricht C, Benesova M, Schmid R, Turler A, Schibli R, van der Meulen N . Sc-PSMA-617 for radiotheragnostics in tandem with Lu-PSMA-617-preclinical investigations in comparison with Ga-PSMA-11 and Ga-PSMA-617. EJNMMI Res. 2017; 7(1):9. PMC: 5247395. DOI: 10.1186/s13550-017-0257-4. View

Milenic D, Brady E, Brechbiel M . Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov. 2004; 3(6):488-99. DOI: 10.1038/nrd1413. View

Sturzbecher-Hoehne M, Yang P, DAleo A, Abergel R . Intramolecular sensitization of americium luminescence in solution: shining light on short-lived forbidden 5f transitions. Dalton Trans. 2016; 45(24):9912-9. DOI: 10.1039/c6dt00328a. View

10.

Bunin D, Chang P, Doppalapudi R, Riccio E, An D, Jarvis E . Dose-dependent efficacy and safety toxicology of hydroxypyridinonate actinide decorporation agents in rodents: towards a safe and effective human dosing regimen. Radiat Res. 2013; 179(2):171-82. PMC: 3633606. DOI: 10.1667/RR3115.1. View

11.

Bandaranayake A, Correnti C, Ryu B, Brault M, Strong R, Rawlings D . Daedalus: a robust, turnkey platform for rapid production of decigram quantities of active recombinant proteins in human cell lines using novel lentiviral vectors. Nucleic Acids Res. 2011; 39(21):e143. PMC: 3241668. DOI: 10.1093/nar/gkr706. View

12.

Pniok M, Kubicek V, Havlickova J, Kotek J, Sabatie-Gogova A, Plutnar J . Thermodynamic and kinetic study of scandium(III) complexes of DTPA and DOTA: a step toward scandium radiopharmaceuticals. Chemistry. 2014; 20(26):7944-55. DOI: 10.1002/chem.201402041. View

13.

Deri M, Ponnala S, Zeglis B, Pohl G, Dannenberg J, Lewis J . Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO). J Med Chem. 2014; 57(11):4849-60. PMC: 4059252. DOI: 10.1021/jm500389b. View

14.

Deshmukh M, Voll G, Kuhlewein A, Macke H, Schmitt J, Kessler H . NMR studies reveal structural differences between the gallium and yttrium complexes of DOTA-D-Phe1-Tyr3-octreotide. J Med Chem. 2005; 48(5):1506-14. DOI: 10.1021/jm0496335. View

15.

Deblonde G, Sturzbecher-Hoehne M, Abergel R . Solution thermodynamic stability of complexes formed with the octadentate hydroxypyridinonate ligand 3,4,3-LI(1,2-HOPO): a critical feature for efficient chelation of lanthanide(IV) and actinide(IV) ions. Inorg Chem. 2013; 52(15):8805-11. PMC: 3771511. DOI: 10.1021/ic4010246. View

16.

Kelley M, Deblonde G, Su J, Booth C, Abergel R, Batista E . Bond Covalency and Oxidation State of Actinide Ions Complexed with Therapeutic Chelating Agent 3,4,3-LI(1,2-HOPO). Inorg Chem. 2018; 57(9):5352-5363. DOI: 10.1021/acs.inorgchem.8b00345. View

17.

Finton K, Larimore K, Larman H, Friend D, Correnti C, Rupert P . Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10. PLoS Pathog. 2013; 9(9):e1003639. PMC: 3784475. DOI: 10.1371/journal.ppat.1003639. View

18.

Price E, Cawthray J, Adam M, Orvig C . Modular syntheses of H₄octapa and H₂dedpa, and yttrium coordination chemistry relevant to ⁸⁶Y/⁹⁰Y radiopharmaceuticals. Dalton Trans. 2014; 43(19):7176-90. DOI: 10.1039/c4dt00239c. View

19.

Deblonde G, Lohrey T, Booth C, Carter K, Parker B, Larsen A . Solution Thermodynamics and Kinetics of Metal Complexation with a Hydroxypyridinone Chelator Designed for Thorium-227 Targeted Alpha Therapy. Inorg Chem. 2018; 57(22):14337-14346. DOI: 10.1021/acs.inorgchem.8b02430. View

20.

Choi T, Endsley A, Bunin D, Colas C, An D, Morales-Rivera J . Biodistribution of the multidentate hydroxypyridinonate ligand [(14) C]-3,4,3-LI(1,2-HOPO), a potent actinide decorporation agent. Drug Dev Res. 2015; 76(3):107-22. DOI: 10.1002/ddr.21246. View